Primary undifferentiated high-grade pleomorphic cardiac sarcoma in the left atrium with atypical presentation

  1. Sue Fen Tan ,
  2. Sherif Osama Ahmed Abbas ,
  3. Nithiananthan Mayooran and
  4. Surendra Kashinath Naik
  1. Cardiac surgery, Nottingham University Hospitals NHS Trust, Nottingham, UK
  1. Correspondence to Dr Sue Fen Tan; esthertan1195@gmail.com

Publication history

Accepted:16 Dec 2022
First published:23 Jan 2023
Online issue publication:23 Jan 2023

Case reports

Case reports are not necessarily evidence-based in the same way that the other content on BMJ Best Practice is. They should not be relied on to guide clinical practice. Please check the date of publication.

Abstract

A woman in her 60s had 4 months of malaise, fatigue, dyspnoea, night sweats and grade 3 clubbing. She had a pansystolic murmur and signs of congestive heart failure. Multimodal imaging with a transthoracic echocardiogram, transoesophageal echocardiogram and CT was carried out to diagnose and reconstruct the mass for surgical planning. A 2×2.8 cm circular dense mass was found in the left atrium with vegetations on the mitral valve. Positron emission tomography and cardiac MRI confirmed the mass’s hypermetabolic activity and malignant features. Mitral valve replacement and surgical resection were performed. She was diagnosed with grade 3 undifferentiated cardiac sarcoma and referred to the sarcoma multidisciplinary team for further management given sarcoma’s rarity and complexity. The poor prognosis of sarcoma was evident as her symptoms recurred 2 months postoperatively.

Background

Primary cardiac sarcoma (PCS) is a rare subset of soft tissue sarcomas with an approximate incidence of 0.001%–0.03%.1 The heterogeneity of symptoms, histological subtypes and response to treatment makes clinical diagnosis and management extremely challenging.

We describe a case of undifferentiated high-grade pleomorphic cardiac sarcomas (UHGPC-SRCSs) with an atypical presentation, which necessitated multimodal imaging and histological diagnosis. The involvement of multidisciplinary team (MDT) was pertinent in managing this complex case due to its poor prognosis and impracticability in ensuring a complete R0 surgical resection.2 This case also discusses the pathognomonic features and histology of sarcoma on imaging, which may help in diagnosing sarcomas.

Case presentation

A woman in her 60s presented with 4 months of malaise. She quickly developed shortness of breath on exertion, easy fatiguability and night sweats. She was deemed to have a chest infection but did not respond to a standard course of antibiotics in the community. Two months later, she noticed clubbing of her fingers and toes. She had intermittent joint swelling of her knees, hands and ankles, which resolved on an episode of night sweat. She experienced occasional palpitations but denied having chest pain, prolonged cough or haemoptysis.

At the time of presentation, the patient appeared lethargic. She had grade 3 finger and toe clubbing bilaterally (see figure 1) and mild pitting pedal oedema bilaterally. She had fine inspiratory crepitation bibasally and moderately loud pan-systolic murmur accentuated with expiration and radiated to the left axilla.

Figure 1

Grade 3 clubbing of fingers and toes.

Investigations

The patient had raised C reactive protein with new onset of microcytic hypochromic anaemia. (CT) of the thorax, abdomen and pelvis demonstrated a tumour mass within the left atrium (see figure 2). Transthoracic echocardiogram (TTE) confirmed a circular dense mass attached to the left atrial septal wall with findings of severe mitral regurgitation and mild aortic regurgitation. Transoesophageal echocardiogram (TOE) showed that a broad-based mass was attached to the lower end of the interatrial septum and extended to the left atrial appendage and the floor of the left atrium (see figure 3). Multiple mobile structures were attached to the mitral leaflets. Positron emission tomography (PET) showed increased activity in the mass within the left atrium (see figure 4) and non-specific activity in some mediastinal lymph nodes, which led to an endobronchial ultrasound bronchoscopy needle aspiration. Only reactive lymphoid tissue without any malignant cells or granuloma was found. Cardiac MRI (CMRI) of the mass suggested tissue features of myxoma and intense enhancement of gadolinium ruled out lymphoma (see figure 5A–F).

Figure 2

A CT thorax demonstrating a left atrial tumour mass (arrow) measuring 17×15 mm with coronary artery calcification.

Figure 3

A preoperative TOE image indicating the size, position and extension of mass. TOE, transoesophageal echocardiogram.

Figure 4

PET showing increased uptake value in the area of mass (arrow) within the heart. PET, positron emission tomography.

Figure 5

(A–F) Multiple chamber views of preoperative CMRI with and without gadolinium contrast depicting an immobile mass within the left atrium with a broad attachment to the aortic wall involving the left atrial appendage (A–F). The mass measures 17×22 mm from a three-chamber view (B), and 30×21 mm from a short axis atrial view (E). The mass appears isointense on T1 (E) and hyperintense on T2. Heterogeneous enhancement is seen in early and late gadolinium sequences (D, F). CMRI, cardiac MRI.

A referral was made to the cardiac surgery department, and the patient was planned for a mitral valve replacement and mass resection simultaneously to obtain a histological diagnosis. The left atrial mass was polypoid with two yellow nodules measuring 30×25×10 mm and 9×10×5 mm (see figure 6). The largest nodule appeared necrotic. The tumour and mitral vegetations contained a haphazard, storiform and fascicular arrangement of predominantly spindle-shaped cells and pleomorphic bizarre cells. There were >50% of necrotic area with calcification and occasional mitoses. A mixed inflammatory infiltrate (plasma cells, neutrophils, histiocytes and occasional lymphocytes) was seen within the tumour, which stained positive for CD31 and EMA. These features (tumour differentiation 3, necrosis 3 and mitoses 1) were consistent with French grade 3 undifferentiated sarcoma.

Figure 6

Gross appearance of the left atrial mass.

Treatment

A biatrial septal approach was used to excise the left atrial tumour and the attached endocardium. The total bypass time was 149 min and the cross-clamp time was 128 min. Her mitral valve was replaced with a 25 mm inverted valve (Inspiris Resilia stented pericardial bioprosthesis) via the conventional median sternotomy approach after excision of the anterior leaflet and infective-looking vegetations. The mass burst intraoperatively and secreted pus-like material. The roof of the left atrium, left main artery and aorta were spared from infiltration.

No adjuvant therapy was performed immediately after the operation as the oncologist advised that it was not necessary in the event of total excision.

Outcome and follow-up

She recovered well from the operation. Once the histological diagnosis was made, she was referred to a regional sarcoma MDT for further management. The first postoperative TTE showed that the mechanical prosthetic valve was well fitted without any tumour recurrence in the left atrium. However, she started experiencing the same symptoms 2 months later while awaiting the MDT outcome and was readmitted to rule out infective endocarditis. A second TTE (see figure 7) and cMRI (see figure 8) revealed that the tumour had recurred in the same position. No distant metastasis was noted. The patient was counselled on the poor prognosis of cardiac sarcoma, and the cardiac surgery team did not think that surgery was feasible at that point. Since it was a local recurrence, the oncologist proposed 5–6 weeks of radical radiotherapy (54 Gy in 30 fractions). Her sarcoma symptoms like night sweats, fever, arthralgia and clubbing have improved since completion of radiotherapy. She had no metastatic disease, and her cardiac function was surprisingly normal.

Figure 7

TOE confirming local recurrence of mass 2 months postoperatively. TOE, transoesophageal echocardiogram.

Figure 8

CMRI confirming local recurrence of mass 2 months postoperatively. CMRI, cardiac MRI.

Discussion

The presentation of PCS is largely dependent on the tumour location.3 This ranges from local effects like arrhythmias, chest pain, tamponade and symptoms of heart failure (pedal oedema, dyspnoea, orthopnoea)1 to non-specific systemic symptoms such as night sweats, cough and fever as seen in our case vignette.4 Different tumours prefer different cardiac sites and chambers.1 UHGPC-SRCSs, also known as malignant fibrous histiocytomas, are commonly found as sessile or pedunculated masses in the left heart and aorta.5 They extend to the myocardium and nearby structures to form large necrotic areas. They contain spindle-shaped cells which are poorly differentiated and exhibit features of high-degree malignancy.6 Therefore, clinicians should attempt to reconstruct the mass preoperatively to plan the optimal surgical approach.5

The investigation should begin with a non-invasive and fast TTE to locate the mass within the heart and grossly evaluate its extension or involvement of other cardiac structures.5 TTE has a sensitivity of 75%–93.3% in identifying cardiac tumours,7 and one of the distinguishing features of malignancy is hypoechogenicity indicating necrosis or haemorrhage.5 To better delineate the tumour, either TOE which has a higher sensitivity of 96% or a contrast echocardiogram can be used.7 The latter can show abnormal tumour vasculature. However, TTE and TOE underestimate cardiac tumour sizes by 20%–25%, and the best way to visualise the tumour is by using a three-dimensional echo as it helps to identify the cleavage plane for surgery.8 Nevertheless, cMRI remains the most powerful non-invasive imaging technique with its high temporal resolution, especially when combined with PET to identify avascular areas of the tumour.5

Cardiac sarcomas should be managed multimodally given their complexity and poor prognosis.3 Complete negative surgical margin (R0) resection and neoadjuvant chemotherapy improve survival,3 but the former is not always feasible.1 Even with R0 or R1/2 resection, the median survival duration is approximately 34.8 and 18.3 months, respectively. This is further corroborated by another independent study, which showed 39 and 18 months of survival in patients who underwent R0 and R1/R2 resections.2 Therefore, aggressive chemoradiotherapy should follow R1/R2 resection, particularly if the tumour is poorly differentiated as there is a high recurrence of neoplasm.5 An innovative surgical technique known as the orthotopic heart autotransplantation involves removing the heart to allow ex vivo tumour resection and reconstruction before the heart is reimplanted, but its efficacy is inconclusive.9 Alternatively, a cyberknife can attain a more precise resection.5

Targeted radiotherapy prevents the destruction of unaffected cardiac muscles, but the clinical response is mixed.5 Similarly, chemotherapy had been used widely with variable results. The first-line agents are adriamycin or ifosfamide and second-line agents include gemcitabine and docetaxel.5 Perhaps markers obtained from immunohistochemistry, which is CD31 in this case, can aid more individualistic immunotherapy. The presence of CD31 suggests either a vascular origin of tumour or vascular invasion (.10 Interestingly, it is also a significant predictor of cardiovascular diseases 11 and may not be the actual tumour immunomarker in this patient who had a strong family history of coronary artery diseases. Nonetheless, the consensus remains that a multidisciplinary approach would benefit the patient most.5

Patient’s perspective

I knew that my disease had come back when I began experiencing the same symptoms. I was surprised at how they came back in the same order, from the night sweats to the joint swelling. I think I am coping well in general, but I found that I am always tired. As I have lost a lot of muscle mass, I don’t seem to have the energy to do things easily anymore. I am bothered about the night sweats and how I need to change my clothes and bedsheet every night.

To be honest, I felt detached from the whole thing, as if it were not happening to me, even though I know the mass is inside. It might be because this is all too big and rare. I found it weird because I am normally anxious about little things, but I was not fazed by all these. I used to have depression and I know how it feels, but I am surprisingly, not depressed. I have been receiving calls and visits from people whom I have lost touch with since they found out about the sarcoma…maybe I just enjoy the feeling of being pampered. I must say, though, that I was annoyed at how my scans were cancelled and rebooked because of COVID-19. I feel that because of the involvement of the MDT, things have progressed much slower than they need to. I was told that I only have limited time to live if I don’t receive my radiotherapy or chemotherapy, so I was a bit disappointed at how slow the MDT was progressing.

Learning points

  • There should be clinical suspicion of primary cardiac sarcoma if the disease is fast progressing to avoid delay in diagnosis as timely surgical resection improves prognosis.

  • Multimodal imaging should be used to reconstruct the mass, starting with transthoracic echocardiogram and followed by more high-definition ones like transoesophageal echocardiogram and cardiac MRI.

  • R0 resection is best theoretically but difficult to achieve in the clinical setting, so management usually involves neoadjuvant or adjuvant chemoradiotherapy.

  • Since undifferentiated high-grade pleomorphic cardiac sarcomas are rare and complex, the management plan should be jointly formulated with sarcoma specialists or multidisciplinary team.

Ethics statements

Patient consent for publication

Footnotes

  • Contributors The case report was written by SFT, SOAA and NM. The patient was under the care of SKN and the case report was supervised by SKN.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

References

Use of this content is subject to our disclaimer